Back to results
US 2022/0033907 A1Published application
Biomarkers
OwnerChris Watson, Mark Ledwidge +3inventors
InventorsChris Watson, Mark Ledwidge, John Baugh, Nadezhda Glezeva, Sudipto Das
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerChris Watson, Mark Ledwidge +3inventors
InventorsChris Watson, Mark Ledwidge, John Baugh, Nadezhda Glezeva, Sudipto Das
Estimating the term…
The invention provides a method of prognosing and/or diagnosing heart disease or heart failure in a subject, comprising determining the methylation status and/or expression level of at least one methylation marker selected from the group consisting of MFSD2B, miR24-1, TTPA, GALNT15, ITGBL1, SMOC2, MSR1, PVT1, MYOM3, COX17, MYBPC3, HEY2, and MRPL44 wherein the methylation status and/or expression level of at least one methylation marker is indicative of the prognosis and/or diagnosis of said subject. A panel of biomarkers, means, a kit and a device for use in assessing risk of HCM, ISCM and DCM are disclosed.
A method of prognosing and/or diagnosing heart disease or heart failure in a subject, comprising
(canceled)
(canceled)
A kit for prognosing and/or diagnosing
A device for identifying heart disease or heart failure in a sample, in particular, HCM, HOCM, ISCM or DCM comprising:
Dependencies are inferred from the claim text.